Non-erosive reflux disease (NERD)

Practical Gastroenterology

Volumn 28, Issue 11, 2004, Pages 14-38

  Fass, Ronnie ^a,b   Dickman, Ram ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CISAPRIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; CLINICAL FEATURE; CLINICAL PRACTICE; ENDOSCOPIC SURGERY; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONEROSIVE REFLUX DISEASE; PHENOTYPE; REVIEW; SYMPTOMATOLOGY;

EID: 10044254552     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Locke G, III, Talley NJ, Fett S, Zinsmeister A, Melton L, III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology, 1997;112:1448-1456.
2. Fass R, Malagon I, Schmulson M. Chest pain of esophageal origin. Curr Opin Gastroenterol, 2001;17:376-380.
3. Richter JE, Castell DO. Gastroesophageal reflux: Pathogenesis, diagnosis, therapy. Ann Intern Med, 1982;97:93-103.
4. Waring JP. Nonerosive reflux disease. Semin Gastroenterol Dis, 2001;12:33-37.
5. Johnsson F, Weywadt L, Solhaug J, Hernqvist H, Bengtsson L. One week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol, 1998;33:15-20.
6. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology, 2000;119:654-660.
7. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology, 1987;92:118-124.
8. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol, 1986;21:837-847.
9. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol, 1997;32:9764-979.
10. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther, 1997; 11(4):765-773.
11. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol, 1998;10(2):119-124.
12. Robinson M, Earnest D, Rodriguez-Stanley S, Greenwood-Van Meerveld B, Jaffe P, Silver MT, Kleoudis CS, Wilson LE, Murdock RH. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med, 1998;158(21):2373-2376.
13. Lind T, Havelund T, Lundel S, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther, 1999;13:907-914.
14. Smout AJ. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther, 1997;11 (Supple 21):81-85.
15. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: Six year follow up of 107 patients. Gut, 1994;35:8-14.
16. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Vijakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol, 1997;92(1):37-41.
17. Sontag S, Schnell T, Chejfec G, et al. Abstract: The benign natural history of GERD: 20 years with rare serious progression. Am J Gastroenterol, 1999;94(2604, #2109).
18. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: A 10 year follow-up of its effect on patient symptomatology and quality of life. Gut, 1996;38:481-486.
19. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol, 1997;119:1161-1167.
20. Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol, 2002;17:949-954.
21. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut, 1991; 32:845-848.
22. Pace F, Porro GB. Gastroesophageal reflux disease: A typical spectrum disease (A new conceptual framework is not needed). Am J Gastroenterol, 2004;99:946-949.
23. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol, 1997;32(10):965-973.
24. Dean BB, Gano A, Jr., Knight K, et al. Effectiveness of proton pump inhibitors in non-erosive reflux disease (NERD). Clin Gastroenterol Hepatol, 2004;2:656-664.
25. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology, 1986;91(4):897-904.
26. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol, 1999;94(8):2054-2059.
27. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Nonerosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther, 2003;17:537-545.
28. Cicala M, Emerenziani S, Caviglia R, Cuarino MP, Vavassori P, Ribolsi M, Carotti S, Petitti T, Pallone F. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2003;18(6):605-613.
29. Weusten BL, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology, 1995;108:1739-1744.
30. Quigley EMM. New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. Aliment Pharmacol Ther, 2003;17(Suppl 2):43-51.
31. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity. Gastroenterology, 1998;115:1363-1373.
32. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut, 1995;37:7-12.
33. Drossman DA. Importance of the psyche in heartburn and dyspepsia. Aliment Pharmacol Ther, 1997;11(Suppl 2):57-67.
34. Johnston BT, Lewis SA, Collins JSA, et al. Acid perception in gastro-oesophageal reflux disease is dependent on psychological factors. Scand J Gastroenterol, 1997;32:974-979.
35. Martinez SD, Malagon I, Garewal H, et al. Abstract: Nonerosive reflux disease (NERD)-is it really just a mild form of gastroesophageal reflux disease (GERD). Gastroenterology, 2001; 120(Suppl 1):A424.
36. Quigley EMM. Non-erosive reflux disease: part of the spectrum of gastro-esophageal reflux disease, a component of functional dyspepsia, or both. Eur J Gastroenterol Hepatol, 2001;13(Suppl 1):S13-S18.
37. Singh S, Richter JE, Bradley LA, et al. The symptom index: differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci, 1993;38:1402-1408.
38. Vaezi M, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology, 1996;111:1192-1199.
39. Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology, 1996;111:1200-1205.
40. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol, 2001; 96(2):303-314.
41. Fass R. Focused clinical review: nonerosive reflux disease. Medscape Gastroenterol, 2001;3(1):1-15.
42. Meyer JH, Lembo A, Elashoff JD, et al. Duodenal fat intensifies the perception of heartburn. Gut, 2001;49:624-628.
43. Bradley LA, Richter JE, Pulliam TJ, et al. The relationship between stress and symptoms of gastroesophageal reflux: The influence of physiological factors. Am J Gastroenterol, 1993;88:11-19.
44. Baker LH, Lieberman D, Koehler M. Psychological distress in patients with gastroesophageal reflux disease. Am J Gastroenterol, 1995;90:1797-1803.
45. Fass R, Pulliam G. Abstract: Chemosensitivity to acid in patients with persistent heartburn on standard doses of proton pump inhibitor and normal 24-h esophageal pH monitoring. Gastroenterology, 1999;116:A159.
46. Niemantsverdriet EC, Timmer R, Breumelhof R, et al. Abstract: Segmental acid sensitivity of the esophagus in patients with endoscopy negative GERD. Gastroenterology, 1997;112:A237.
47. DeVault KR, Castell DO, and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol, 1999;94:1434-1442.
48. Inflammatory disorders of the esophagus: reflux and nonreflux types. In: Lewin KJ, Riddell RH, Weinstein WM, editors. Gastrointestinal Pathology and Its Clinical Implications. New York: Igaku-Shoin; 1992. p. 401-439.
49. Funch-Jensen P, Kock K, Christensen LA, et al. Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings. Scand J Gastroenterol, 1986;21:65-69.
50. Schindlbeck NE, Weibecke B, Klauser AG, et al. Diagnostic value of histology in non-erosive gastro-oesophageal reflux disease. Gut, 1996;39:151-154.
51. Kahrilas PJ, Quigley EMM. American Gastrointestinal Association medical position statement: Guidelines on the use of esophageal pH recording. Gastroenterology, 1996;110:1981-1996.
52. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive esophagus": Gut, 1997; 40(5):587-590.
53. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther, 2000;14:389-396.
54. Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med, 1999;159:2161-2168.
55. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost effectiveness of the omeprazole test in non-cardiac chest pain. Am J Med, 1999;107:219-227.
56. Schindlbeck NE, Klauser AG, Voderholzer WA, et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med, 1995;155:1808-1812.
57. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol, 1997;92:1997-2000.
58. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 mg once daily, omeprazole 20 mg once daily or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastroesophageal reflux in general practice. Scand J Gastroenterol, 1997;32:965-973.
59. Fennerty MB, Lieberman D. H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease. For whom the bell tolls. Gastroenterology, 1994;107:1545-1548.
60. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology, 1997;112:1798-1810.
61. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastro-esophageal reflux disease. Arch Intern Med, 2000;160:1803-1809.
62. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med, 2000;160:1810-1816.
63. Fenton P, Terry ML, Galloway K, et al. Abstract: Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? Gastroenterology; 2000;118(4, Suppl 2):A481, #2600.
64. Khajanchee YS, Hong D, Hansen PD, Swanstrom LL. Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg, 2004;187(5):599-603.
65. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework. Am J Gastroenterol, 2002; 97:1901-1909.
66. The Gallup Organization Inc. Understanding Heartburn in America, 2000.
67. Bardhan KD, Müller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J, 1999;318:502-507.
68. Stalhammar NO, Carlsson R, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics, 1999;16:483-497.
69. Bardhan KD. Omeprazole in the treatment of gastroesophageal reflux disease. In: Scarpignato C, editor. Advances in Drug Therapy of Gastroesophageal Reflux Disease. Basal: Karger; 1992.